Cancer Drug May Not Get A Chance Due to Lack of Patent

Researchers at the University of Alberta Department of Medicine have shown that an existing small, relatively non-toxic molecule, dichloroacetate, causes regression in several different cancers. But there’s a catch: the drug isn’t patented, and pharmaceutical companies may not be interested in funding further research if the treatment won’t make them a profit. In findings that astounded the researchers, the molecule known as DCA was shown to shrink lung, breast and brain tumours in both animal and human tissue experiments